G.B. Cassano, P. Castrogiovanni, M. Mauri, G. Rutigliano, R. Pirro, G. Cerone, N.P. Nielsen, S. Reitano, N. Guidotti, D. Bedarida, F.P. Marchetti, A. Catalano, M.V. Benecchi, G. Amabile, M. Zanasi, L. Pugliese, M.L. Rocco, A. Balestrieri, M. Tansella, L. Burti, F. Pariante
{"title":"恐惧症-强迫性精神神经症的多中心对照试验。氯丙咪嗪及其与氟哌啶醇和地西泮联用的效果","authors":"G.B. Cassano, P. Castrogiovanni, M. Mauri, G. Rutigliano, R. Pirro, G. Cerone, N.P. Nielsen, S. Reitano, N. Guidotti, D. Bedarida, F.P. Marchetti, A. Catalano, M.V. Benecchi, G. Amabile, M. Zanasi, L. Pugliese, M.L. Rocco, A. Balestrieri, M. Tansella, L. Burti, F. Pariante","doi":"10.1016/0364-7722(81)90061-8","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>1.</span><span><p>1. Chlorimipramine has been reported to be effective in the treatment of phobic-obsessive patients. It has been widely used in combination with anti-anxiety compounds such as benzodiazepines, or with major tranquillizers, such as butirophenones, but no clear-cut superiority of anyone of these treatments has been yet established.</p></span></li><li><span>2.</span><span><p>2. A multicenter trial was performed to compare the therapeutic characteristics of chlorimipramine alone with those displayed in combination with haloperidol or diazepam in patients showing an obsessive and/or phobic sympomatology.</p></span></li><li><span>3.</span><span><p>3. A total of 54 inpatients of both sexes were admitted to a 60-day trial and were treated in double-blind conditions. The experiment was carried-out in three groups: chlorimipramine, chlorimipramine and diazepam, and chlorimipramine and haloperidol.</p></span></li><li><span>4.</span><span><p>4. The psychopatological picture and the evaluation of clinical efficacy was assessed by a battery of instruments: the MMPI, the RSD of Hamilton, the BPRS of Overall and Gorham and the IMPS of Lorr. For safety a check-list of side-effects has been used.</p></span></li><li><span>5.</span><span><p>5. After statistical processing, the data gathered from various centres seem to indicate differentiated types of response in all three treatments. These data suggest a possible differentiation in the use of the three treatments.</p></span></li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90061-8","citationCount":"12","resultStr":"{\"title\":\"A multicenter controlled trial in phobic-obsessive psychoneurosis. The effect of chlorimipramine and of its combinations with haloperidol and diazepam\",\"authors\":\"G.B. Cassano, P. Castrogiovanni, M. Mauri, G. Rutigliano, R. Pirro, G. Cerone, N.P. Nielsen, S. Reitano, N. Guidotti, D. Bedarida, F.P. Marchetti, A. Catalano, M.V. Benecchi, G. Amabile, M. Zanasi, L. Pugliese, M.L. Rocco, A. Balestrieri, M. Tansella, L. Burti, F. Pariante\",\"doi\":\"10.1016/0364-7722(81)90061-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>1.</span><span><p>1. Chlorimipramine has been reported to be effective in the treatment of phobic-obsessive patients. It has been widely used in combination with anti-anxiety compounds such as benzodiazepines, or with major tranquillizers, such as butirophenones, but no clear-cut superiority of anyone of these treatments has been yet established.</p></span></li><li><span>2.</span><span><p>2. A multicenter trial was performed to compare the therapeutic characteristics of chlorimipramine alone with those displayed in combination with haloperidol or diazepam in patients showing an obsessive and/or phobic sympomatology.</p></span></li><li><span>3.</span><span><p>3. A total of 54 inpatients of both sexes were admitted to a 60-day trial and were treated in double-blind conditions. The experiment was carried-out in three groups: chlorimipramine, chlorimipramine and diazepam, and chlorimipramine and haloperidol.</p></span></li><li><span>4.</span><span><p>4. The psychopatological picture and the evaluation of clinical efficacy was assessed by a battery of instruments: the MMPI, the RSD of Hamilton, the BPRS of Overall and Gorham and the IMPS of Lorr. For safety a check-list of side-effects has been used.</p></span></li><li><span>5.</span><span><p>5. After statistical processing, the data gathered from various centres seem to indicate differentiated types of response in all three treatments. These data suggest a possible differentiation in the use of the three treatments.</p></span></li></ul></div>\",\"PeriodicalId\":20801,\"journal\":{\"name\":\"Progress in neuro-psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0364-7722(81)90061-8\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in neuro-psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0364772281900618\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neuro-psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0364772281900618","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A multicenter controlled trial in phobic-obsessive psychoneurosis. The effect of chlorimipramine and of its combinations with haloperidol and diazepam
1.
1. Chlorimipramine has been reported to be effective in the treatment of phobic-obsessive patients. It has been widely used in combination with anti-anxiety compounds such as benzodiazepines, or with major tranquillizers, such as butirophenones, but no clear-cut superiority of anyone of these treatments has been yet established.
2.
2. A multicenter trial was performed to compare the therapeutic characteristics of chlorimipramine alone with those displayed in combination with haloperidol or diazepam in patients showing an obsessive and/or phobic sympomatology.
3.
3. A total of 54 inpatients of both sexes were admitted to a 60-day trial and were treated in double-blind conditions. The experiment was carried-out in three groups: chlorimipramine, chlorimipramine and diazepam, and chlorimipramine and haloperidol.
4.
4. The psychopatological picture and the evaluation of clinical efficacy was assessed by a battery of instruments: the MMPI, the RSD of Hamilton, the BPRS of Overall and Gorham and the IMPS of Lorr. For safety a check-list of side-effects has been used.
5.
5. After statistical processing, the data gathered from various centres seem to indicate differentiated types of response in all three treatments. These data suggest a possible differentiation in the use of the three treatments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
